NCT06421142 FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
| NCT ID | NCT06421142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Urinary Bladder Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-08-02 |
| Primary Completion | 2028-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-08-02 with a primary completion date of 2028-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.
Eligibility Criteria
Inclusion Criteria: * Inclusion criteria for MIBC diagnostic studies 1. Patients with suspected muscle-invasive bladder cancer; 2. Completion of FAPI PET/MRI, FDG PET/MRI and MRI; 3. Complete clinical laboratory and pathological data. * Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study 1. Patients diagnosed with muscle invasive bladder cancer; 2. Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy; 3. Complete clinical laboratory and pathological data. Exclusion Criteria: * Exclusion criteria for MIBC diagnostic study 1. Combined with other malignant tumors; 2. Not receiving surgical treatment; 3. Receiving neoadjuvant therapy before surgery; 4. Previous allergy to contrast components or similar components; 5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities; 6. Incomplete clinicopathological data * Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study 1. Combination of other malignant tumors; 2. FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy; 3. Prior hypersensitivity to contrast components or similar components; 4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function; 5. Incomplete clinicopathological data.
Contact & Investigator
Xue-Yi Xue, Master
STUDY CHAIR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT06421142 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Urinary Bladder Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06421142 currently recruiting?
Yes, NCT06421142 is actively recruiting participants. Contact the research team at drxun@fjmu.edu.cn for enrollment information.
Where is the NCT06421142 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT06421142 clinical trial?
NCT06421142 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Xue-Yi Xue, Master at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 80 participants.